• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Oligodendroglioma - Pipeline Review, H2 2012 Product Image

Oligodendroglioma - Pipeline Review, H2 2012

  • ID: 2298690
  • October 2012
  • 69 pages
  • Global Markets Direct

Oligodendroglioma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Oligodendroglioma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. Oligodendroglioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oligodendroglioma.
- A review of the Oligodendroglioma products under development by companies and universities/research institutes READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Oligodendroglioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oligodendroglioma 9
Oligodendroglioma Therapeutics under Development by Companies 11
Oligodendroglioma Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Oligodendroglioma Therapeutics – Products under Development by Companies 18
Oligodendroglioma Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Oligodendroglioma Therapeutics Development 20
Tocagen Inc 20
Oligodendroglioma – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
irinotecan hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MLN-518 + Bevacizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
Temozolomide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
imatinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Temozolomide + Busulfan + Thiotepa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
Temozolomide + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
topotecan hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
temozolomide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Bevacizumab + Irinotecan - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Peptide Vaccine + Poly-ICLC - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
bendamustine hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
temozolomide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
everolimus - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
Imatinib Mesylate + Temozolomide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Etoposide + Melphalan + Carboplatin + Sodium Thiosulfate + Filgrastim + Neulasta - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 52
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Autologous Tumor Cell Vaccine + Sargramostim + Muromonab-CD3 + Aldesleukin + Radiation Therapy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
Toca 511 + Toca FC - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
nintedanib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Lomustine + Procarbazine + Vincristine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
carmustine SR Implant - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
carboplatin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Oligodendroglioma Therapeutics – Drug Profile Updates 64
Oligodendroglioma Therapeutics – Discontinued Products 66
Oligodendroglioma Therapeutics - Dormant Products 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
Number of Products Under Development for Oligodendroglioma, H2 2012 9
Products under Development for Oligodendroglioma – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Tocagen Inc, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Oligodendroglioma Therapeutics – Drug Profile Updates 64
Oligodendroglioma Therapeutics – Discontinued Products 66
Oligodendroglioma Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Oligodendroglioma, H2 2012 9
Products under Development for Oligodendroglioma – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos